Sharp Corp. narrowed its full-year loss outlook after posting its first quarterly profit in more than two years, lifted by cost reductions and a turnaround in the display business. The net loss will reach 37.2 billion yen in the year ending March 31, the Osaka-based company reported on Friday.
Category: Osaka, Japan
Takeda Expands Cancer Business With $4.66 Billion Ariad Deal
Takeda Pharmaceutical Co. will expand its footprint in the U.S. oncology market with the $4.66 billion purchase of Ariad Pharmaceuticals Inc., adding one potential blockbuster in lung cancer and another already on-the-market therapy.
No Room For The Inn as Japanese Informal Accommodation Booms
All is not well in the world of Japanese hospitality. There appears to be a structural shift under way in the market that investors should not ignore.